520 related articles for article (PubMed ID: 8311993)
1. Down syndrome--a gene dosage disease caused by trisomy of genes within a small segment of the long arm of chromosome 21, exemplified by the study of effects from the superoxide-dismutase type 1 (SOD-1) gene.
Annerén G; Edman B
APMIS Suppl; 1993; 40():71-9. PubMed ID: 8311993
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of chromosome 21 in a patient with a phenotype of Down syndrome and apparently normal karyotype.
Ahlbom BE; Goetz P; Korenberg JR; Pettersson U; Seemanova E; Wadelius C; Zech L; Annerén G
Am J Med Genet; 1996 Jun; 63(4):566-72. PubMed ID: 8826436
[TBL] [Abstract][Full Text] [Related]
3. Evidence against the current hypothesis of "gene dosage effects" of trisomy 21: ets-2, encoded on chromosome 21" is not overexpressed in hearts of patients with Down Syndrome.
Greber-Platzer S; Schatzmann-Turhani D; Wollenek G; Lubec G
Biochem Biophys Res Commun; 1999 Jan; 254(2):395-9. PubMed ID: 9918849
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene.
Groner Y; Elroy-Stein O; Avraham KB; Yarom R; Schickler M; Knobler H; Rotman G
J Physiol (Paris); 1990; 84(1):53-77. PubMed ID: 1972759
[TBL] [Abstract][Full Text] [Related]
5. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III).
Cheon MS; Kim SH; Ovod V; Kopitar Jerala N; Morgan JI; Hatefi Y; Ijuin T; Takenawa T; Lubec G
Amino Acids; 2003; 24(1-2):127-34. PubMed ID: 12624744
[TBL] [Abstract][Full Text] [Related]
6. Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms.
Rachidi M; Lopes C
Neurosci Res; 2007 Dec; 59(4):349-69. PubMed ID: 17897742
[TBL] [Abstract][Full Text] [Related]
7. Tetrasomy 21 pter-->q22.1 and Down syndrome: molecular definition of the region.
Daumer-Haas C; Schuffenhauer S; Walther JU; Schipper RD; Porstmann T; Korenberg JR
Am J Med Genet; 1994 Dec; 53(4):359-65. PubMed ID: 7532356
[TBL] [Abstract][Full Text] [Related]
8. Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome.
Amano K; Sago H; Uchikawa C; Suzuki T; Kotliarova SE; Nukina N; Epstein CJ; Yamakawa K
Hum Mol Genet; 2004 Jul; 13(13):1333-40. PubMed ID: 15138197
[TBL] [Abstract][Full Text] [Related]
9. Using mouse models to explore genotype-phenotype relationship in Down syndrome.
Salehi A; Faizi M; Belichenko PV; Mobley WC
Ment Retard Dev Disabil Res Rev; 2007; 13(3):207-14. PubMed ID: 17910089
[TBL] [Abstract][Full Text] [Related]
10. Human chromosome 21q22.2-qter carries a gene(s) responsible for downregulation of mlc2a and PEBP in Down syndrome model mice.
Kazuki Y; Kimura M; Nishigaki R; Kai Y; Abe S; Okita C; Shirayoshi Y; Schulz TC; Tomizuka K; Hanaoka K; Inoue T; Oshimura M
Biochem Biophys Res Commun; 2004 Apr; 317(2):491-9. PubMed ID: 15063784
[TBL] [Abstract][Full Text] [Related]
11. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype.
Korenberg JR; Kawashima H; Pulst SM; Ikeuchi T; Ogasawara N; Yamamoto K; Schonberg SA; West R; Allen L; Magenis E
Am J Hum Genet; 1990 Aug; 47(2):236-46. PubMed ID: 2143053
[TBL] [Abstract][Full Text] [Related]
12. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part I).
Cheon MS; Kim SH; Yaspo ML; Blasi F; Aoki Y; Melen K; Lubec G
Amino Acids; 2003; 24(1-2):111-7. PubMed ID: 12624742
[TBL] [Abstract][Full Text] [Related]
13. Genetic mechanisms involved in the phenotype of Down syndrome.
Patterson D
Ment Retard Dev Disabil Res Rev; 2007; 13(3):199-206. PubMed ID: 17910086
[TBL] [Abstract][Full Text] [Related]
14. Maternal balanced translocation (4;21) leading to an offspring with partial duplication of 4q and 21q without phenotypic manifestations of Down syndrome.
El-Ruby M; Hemly NA; Zaki MS
Genet Couns; 2007; 18(2):217-26. PubMed ID: 17710874
[TBL] [Abstract][Full Text] [Related]
15. The "gene dosage effect" hypothesis versus the "amplified developmental instability" hypothesis in Down syndrome.
Pritchard MA; Kola I
J Neural Transm Suppl; 1999; 57():293-303. PubMed ID: 10666684
[TBL] [Abstract][Full Text] [Related]
16. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells.
Lemieux N; Malfoy B; Forrest GL
Genomics; 1993 Jan; 15(1):169-72. PubMed ID: 8432528
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice overexpressing the human Cu/Zn-SOD gene: ultrastructural studies of a premature thymic involution model of Down's syndrome (trisomy 21).
Nabarra B; Casanova M; Paris D; Nicole A; Toyama K; Sinet PM; Ceballos I; London J
Lab Invest; 1996 Mar; 74(3):617-26. PubMed ID: 8600312
[TBL] [Abstract][Full Text] [Related]
18. Increased superoxide dismutase and Down's syndrome.
Turrens JF
Med Hypotheses; 2001 Jun; 56(6):617-9. PubMed ID: 11399108
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in the adult Down syndrome brain.
Lockstone HE; Harris LW; Swatton JE; Wayland MT; Holland AJ; Bahn S
Genomics; 2007 Dec; 90(6):647-60. PubMed ID: 17950572
[TBL] [Abstract][Full Text] [Related]
20. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part II).
Cheon MS; Bajo M; Kim SH; Claudio JO; Stewart AK; Patterson D; Kruger WD; Kondoh H; Lubec G
Amino Acids; 2003; 24(1-2):119-25. PubMed ID: 12624743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
